This result is consistent with previous reports that the pharmacological inhibition of EZH2 leads to down-regulation of CCND1 in skin cancer, and CCND1 is linked to the malignant progression of oral premalignancy [85]. This evidence concerns the gene CCND1 and skin cancer.